C12N 2310/3529
Aromatic substituent
C12N2310/3529 (Aromatic substituent) appears on 9 US grants and 15 published applications in this corpus.
Search patents in C12N- Granted patents
- 9
- Published applications
- 15
- Assignees
- 6
- Inventors
- 26
- Latest grant
- 2 Oct 2018
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2010 | 0 | 1 |
| 2011 | 1 | 0 |
| 2012 | 0 | 4 |
| 2013 | 3 | 2 |
| 2014 | 0 | 0 |
| 2015 | 1 | 2 |
| 2016 | 3 | 0 |
| 2017 | 0 | 1 |
| 2018 | 1 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 4 |
| 2025 | 0 | 1 |
By publication year.
Recent patents
- Modifications for antisense compounds2 Oct 2018US 10,087,445 B2Integrated Dna Technologies, Inc.
- Modifications for antisense compounds29 Nov 2016US 9,506,059 B2Integrated Dna Technologies, Inc.
- Short interfering ribonucleic acid (siRNA) for oral administration15 Nov 2016US 9,493,771 B2Novartis AG
- Base modified oligonucleotides16 Aug 2016US 9,416,360 B2Miragen Therapeutics, Inc.
- Short interfering ribonucleic acid (siRNA) for oral administration17 Feb 2015US 8,957,041 B2Novartis AG
- Pharmaceutical composition for preventing or treating triple-negative breast cancer, comprising oligonucleotide as active ingredient4 Dec 2025US 2025/0367301 A1Interoligo Corporation
- Pharmaceutical composition for treating triple negative breast cancer, containing non-natural nucleic acid ligand as active ingredient10 Oct 2024US 2024/0336926 A1Interoligo Corporation
- Non-natural nucleic acid ligand, uses thereof, and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient3 Oct 2024US 2024/0327848 A1Interoligo Corporation
- Ligand-binding nucleic acid complex22 Aug 2024US 2024/0279655 A1Rena Therapeutics Inc.
- Novel peptide-oligonucleotide conjugate and use thereof13 Jun 2024US 2024/0189435 A1Korea Institute of Science and Technology
Most cited
By later US patents
- Short interfering ribonucleic acid (siRNA) with improved pharmacological properties32US 8,084,600 B2Novartis AG · 2011
- Short interfering ribonucleic acid (siRNA) for oral administration14US 8,344,128 B2Novartis AG · 2013
- Short interfering ribonucleic acid (siRNA) for oral administration12US 8,404,831 B2Novartis AG · 2013
- Short interfering ribonucleic acid (siRNA) for oral administration8US 8,404,832 B2Novartis AG · 2013